Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Arena Pharmaceuticals, Inc.    

ARENA PHARMACEUTICALS, INC.
Mes dernières consult.
Most popular
  Report  
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Arena Pharmaceuticals, Inc. : Five Star Equities Issues New Research Reports on ARNA, DD, KR and VECO

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/17/2013 | 03:05pm CEST

Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) shares hit a low of $7.70 Friday before settling to close at $7.78, a decrease of 6.71 percent. The stock traded in between $7.70 to $8.30 on volume of 8.97 million shares traded. Consumer Reports has recently advised their readers to ?skip? Arena?s weight loss drug, Belviq.

Get more information on Arena Pharmaceuticals and free access to the in-depth equity report at:
www.FiveStarEquities.com/ARNA

E I Du Pont De Nemours And Co (NYSE: DD) shares hit a low of $52.16 Friday before settling to close at $52.68, a decrease of 2.23 percent. The stock traded in between $52.16 to $53.70 on volume of 11.28 million shares traded. Jefferies Group currently has a ?hold? rating on the stock and has recently raised its price target on the company to $56.00 from $52.00.

Get more information on Du Pont and free access to the in-depth equity report at:
www.FiveStarEquities.com/DD

The Kroger Co. (NYSE: KR) hit a low of $34.67 Friday before settling to close at $34.79, a decrease of 0.77 percent. The stock traded in between $34.67 to $35.25 on volume of 2.46 million shares traded. Argus currently has a ?buy? rating on the stock and has recently raised its price target on the company to $40.00 from $34.00.

Get more information on Kroger and free access to the in-depth equity report at:
www.FiveStarEquities.com/KR

Veeco Instruments Inc. (NASDAQ: VECO) shares hit a low of $37.74 Friday before settling to close at $38.10, a decrease of 3.20 percent. The stock traded in between $37.74 and $39.04 on volume of 559,990 shares traded. UBS has reiterated it ?neutral? view on the company due to pricing pressure pricing pressure Veeco?s metal organic vapor deposition epitaxial systems.

Get more information on Veeco Instruments and free access to the in-depth equity report at:
www.FiveStarEquities.com/VECO

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Wall Street Fundamentals has no financial relationship with any company whose stock is mentioned in this release.

Contact:
Five Star Equities
[email protected]


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ARENA PHARMACEUTICALS, INC
04/17ARENA PHARMACEUTICALS : Announces Phase 2 Data Presentation for Ralinepag in Pul..
AQ
04/12ARENA PHARMACEUTICALS : Announces Phase 2 Data Presentation for Ralinepag in Pul..
PR
04/02ARENA PHARMACEUTICALS INC : Other Events (form 8-K)
AQ
03/29ARENA PHARMACEUTICALS : Announces Pricing of Public Offering of Common Stock
AQ
03/29ARENA PHARMACEUTICALS : Reports Positive Phase 2 Results from the OASIS Trial fo..
AQ
03/29ARENA PHARMACEUTICALS : Announces Proposed Public Offering of Common Stock
AQ
03/29ARENA PHARMACEUTICALS : Announces Completion of Public Offering of Common Stock ..
AQ
03/26ARENA PHARMACEUTICALS : Announces Completion of Public Offering of Common Stock ..
PR
03/26ARENA PHARMACEUTICALS : Announces Pricing of Public Offering of Common Stock
AQ
03/24ARENA PHARMACEUTICALS : to Present at the 17th Annual Needham Healthcare Confere..
PR
More news
News from SeekingAlpha
2017Arena Pharmaceuticals (ARNA) Presents At JMP Securities Life Sciences Confere.. 
2017Arena Pharmaceuticals' (ARNA) CEO Amit Munshi Presents at JMP Securities Life.. 
2017Arena continues up move, shares ahead 25% in three days 
2017DRYSHIPS : Rank #1 As Worst Stock In Nasdaq 
2017Stocks to watch next week 
Financials ($)
Sales 2018 12,1 M
EBIT 2018 -114 M
Net income 2018 -116 M
Finance 2018 143 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 144x
EV / Sales 2019 155x
Capitalization 1 896 M
Chart ARENA PHARMACEUTICALS, INC
Duration : Period :
Arena Pharmaceuticals, Inc Technical Analysis Chart | US0400471027 | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 61,9 $
Spread / Average Target 58%
EPS Revisions
Managers
NameTitle
Amit Dilip Munshi President, Chief Executive Officer & Director
Tina Susan Nova Chairman
Kevin R. Lind Chief Financial Officer & Executive Vice President
John Adams Head-Scientific Affairs
Preston S. Klassen Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ARENA PHARMACEUTICALS, INC.14.01%1 896
CELLTRION, INC.--.--%31 379
IQVIA HOLDINGS INC-1.18%20 258
LONZA GROUP-7.06%18 717
INCYTE CORPORATION-34.17%14 493
NEKTAR THERAPEUTICS43.08%13 873